Abstract
Stigma has become a primary social force facing patients in methadone and buprenorphine treatment. For quality methadone and buprenorphine treatment to flourish it will be necessary to confront and reduce this negative influence. This article, co-authored by a patient and professional, discusses stigma and prejudice from the viewpoint of patients. Educational and national strategies using the media and targeted to patients, programs, and the general public are discussed.
Notes
a. Suboxone is a combination of buprenorphine and naloxone to deter diversion. However it has not really worked since buprenorphine by itself has a greater affinity for the mu receptor than methadone or heroin and can produce withdrawal symptoms if an opioid dependent person injects buprenorphine without the inclusion of naloxone. There have been widespread reports of Suboxone diversion.
b. On June 9, 2015 an act (S.4239-B /A.6255-B) to amend the criminal procedure law, in relation to authorizing eligible defendants, in the judicial diversion program (drug courts) who need treatment for opioid abuse or dependence, to receive certain medically prescribed treatment was passed by both New York legislatures. The bill has been returned to the New York Assembly for an alteration and will be considered again in the January 2016 session of the legislature. If passed, the bill will be submitted to Governor Cuomo for his signature. The death of Robert Lepolszki was mentioned in the legislation that will prevent judges and probation and parole officers from forcing individuals receiving methadone and buprenorphine treatment off their medication.